ReviewCurrent protein & peptide science2026
Targeting Cdc42: Novel Approaches in Cardiovascular Disorders.
Review in Current protein & peptide science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide, and need novel molecular targets for improved diagnosis and treatment. There are some potential new molecular targets for CVD treatment, including miRNAs, C-reactive protein, interleukins, fibrinogen, monocyte chemotactic protein-1, etc. One of the newer targets can be cell division control protein 42 homolog (Cdc42), a small GTPase of the Rho family, which has a significant role in cardiovascular physiology and pathology. This review focuses on demonstrating multifaceted functions of Cdc42 in cardiovascular complications, including vascular endothelial function, vascular smooth muscle cell regulation, cardiac myocyte development, inflammatory responses, and lipid metabolism. This review highlights the importance of Cdc42 in maintaining endothelial barrier integrity, regulating vascular smooth muscle cell phenotype, cardiac development, immune response modulation, and influencing lipid transport and insulin signalling. Furthermore, this review comprehensively explores the potential of Cdc42 as a biomarker for early CVD detection and proves to be a beneficial therapeutic target. This review also addresses the challenges in targeting Cdc42, given its ubiquitous nature, and directs future research, including tissue-specific modulation strategies and exploration of downstream signalling effectors. This review aims to potentiate future research by utilizing the current data on Cdc42 signalling in the cardiovascular system and constructing a bridge for innovative therapeutic approaches in CVD prevention and treatment. Cdc42 regulates cardiovascular processes, including endothelial function, vascular smooth muscle behaviour, cardiac development, inflammation, and metabolism. Additionally, evidence demonstrates Cdc42's involvement in key signalling pathways affecting lipid metabolism and insulin sensitivity.
Indexed as
Identifiers
40739684What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.